TNXP - Tonix Pharmaceuticals Holding Corp.

Top Stock Signal for 05-13-2022
Loading Chart TNXP

Stock Signal Information


Penny Stock Signal: TNXP
Report Date: 05-13-2022
Company: Tonix Pharmaceuticals Holding Corp. (TNXP)
Sector: Healthcare
Industry: Biotechnology

TNXP Technical Analysis

Company Contact

Tonix Pharmaceuticals Holding Corp. (TNXP)
New York City, NEW YORK 10022
Phone: 18008497894
Website: http://www.tonixpharma.com
CEO: Dr. Seth Lederman

TNXP, Tonix Pharmaceuticals Holding Corp.

TNXP Tonix Pharmaceuticals Holding Corp. Logo Image

NASDAQ, Nasdaq Global Market

Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) portfolio comprises small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300, a second live replicating vaccine candidate for the prevention of COVID-19 that employs bovin parainfluenza virus as the vector. In addition, the company's lead CNS candidate is TNX-102 SL, which is in Phase 3 development for the management of fibromyalgia, as well as in Phase 2 studies for agitation in Alzheimer's disease and alcohol use disorder. Further, its products include TNX-1300, which is in Phase 2 development for the treatment of life-threatening cocaine intoxication; TNX-601 CR (tianeptine oxalate controlled-release tablets) that is in Phase 1 development for depression; and TNX-1900, an intranasal oxytocin as a non-addictive treatment for migraine and cranio-facial pain. Additionally, its preclinical pipeline includes TNX-1600, a triple reuptake inhibitor for posttraumatic stress disorder; TNX-1500, a monoclonal antibody to prevent and treat organ transplant rejection and autoimmune conditions; and TNX 1700, a recombinant modified form of Trefoil Family Factor 2 to treat gastric and pancreatic cancers. The company was founded in 2007 and is based in New York, New York.

Top Stock Signals

free stock market signals, daily stock signals, stock option trading signals

About Top Stock Signals

Good stock signals have been found on this server. That is all we know.

Phone: +1 (407) 559-7228
Email: [email protected]

About Us | Newsletter | Members

Most Active
Top Gainers
Top Losers